Cell Line Development, 3D Cell Culture and Immuno-Oncology Research (In Vivo)

This is an overview capabilities brochure of the services and expertise August Bioservices offers to biotech and pharma companies of all sizes. As a growing, US-based provider of expert CDMO services, August is rapidly becoming a preferred partner for clients seeking deep drug development, formulation, sca...

August Bioservices has a Binding Technologies Toolbox that is second to none. These case studies highlight our biophysical characterization capabilities, including the state-of-the-art TRIC (Temperature Related Intensity Change) technology which can provide new insights into protein-small molecule binding ...

August Bioservices can provide clinical and commercial manufacturing fill finish services - with supporting formulation development, scale up and analytical testing capabilities - across a wide range of injectable products, container sizes and fill volumes.
Vials - from 1/2 mL up to 500 mL
Syringes...

What you need to seamlessly transition from clinical phases to commercial readiness.

Three unique abilities your CDMO must have to complete your project within your timeline are capability, flexibility and availability.


August Bioservices' Director of Customer Operations, Commercial Devel...

August Bioservices is a US-based CDMO offering end to end outsourced services that support our pharma and biotech clients' projects throughout the drug discovery, development and manufacturing lifecycle.

This piece highlights the company's $65 million expansion investment and the impact on the local...

Welcome to August Bioservices At August Bioservices, we are a US-based, world-class CDMO specializing in sterile injectable drug development and manufacturing. With a full spectrum of capabilities from early-stage formulation to commercial production, we partner with clients to bring life-changing therapies to patients faster. Our team of industry experts, cutting-edge technology, and flexible, scalable solutions are built to meet your product’s unique needs at every stage.

Bringing a sterile injectable product from development to commercialization requires a seamless scale-up process—one that minimizes risk, optimizes efficiency, and ensures regulatory success. In this exclusive webinar, experts from August Bioservices will discuss the critical factors that make or break a successful scale-up, sharing insights from a CDMO’s unique perspective.

Watch as 12 months of construction unfolds before your eyes in 30 seconds.

The facility expansion shown here is adding to August Bioservices' Nashville, TN, USA campus:


- 3 new formulation suites
- 2 new filling suites for high-speed vial and PFS lines
- significant warehousing capacity
- redundant utilities
- multi-bay loading dock

August Bioservices, a US-based CDMO, is expanding its current facility and is building a new facility immediately adjacent to its existing building that will house drug discovery, development, formulation, scale up, analytical testing, and clinical and commercial manufacturing - all "under one roof", on one contiguous campus in Nashville, TN.

With a strong focus on sterile injectables and decades of commercialization experience across the leadership team, August Bioservices' manufacturing capabilities can handle a wide range of container sizes and fill volumes.


Vials - 1/2 mL to 500 mL
Bags - 25 mL to 5 L
Syringes - 1/4 mL to 50 mL


As can be seen in this video, August's growth initiatives continue to receive exceptional support from all levels of government and industry in the state of TN.